Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome.

Record Detail

Save:
Title:	Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome.
Author:	Kaufman, L D : Gruber, B L : Gregersen, P K
Citation:	Lancet. 1991 May 4; 337(8749): 1071-4
Abstract:	31 patients with L-tryptophan-associated eosinophilia-myalgia syndrome (EMS) that developed during the United States outbreak in 1989 were followed up prospectively at a university hospital outpatient rheumatology clinic for 16 to 24 months from the onset of their illness. Another patient with EMS associated with L-tryptophan in 1988 was followed up for 30 months. 93% of the 28 survivors from the 1989 cohort continue to have symptoms affecting 1-4 organ systems (median 3) and 3 have died, so the disorder produces considerable morbidity and mortality. The chronic sequelae most often associated with long-term disability are sclerodermatous skin thickening (54%), sensorimotor polyneuropathy (61%), proximal myopathy (36%), and severe episodic myalgias (64%). Thrombocytopenia developed in 1 patient. HLA-class II typing revealed a non-significant trend towards an association with HLA-DR4. Early therapy with corticosteroids did not seem to prevent the development of chronic manifestations.
Review References:	None
Notes:	Copyright The Lancet. Abstracts are reprinted by the permission of the publisher of the journal for volume, pages, and dates cited. Hypertext links to electronic journal sites, if available, can be found in the the Peer Reviewed Journal List on the IBIDS home page.
Language:	English
Publication Type:	Journal-Article
Keywords:	Eosinophilia complications : Muscular Diseases complications
URL:	http://www.elsevier.com/locate/issn/01406736